

Ding-Shinn Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1336984/publications.pdf>

Version: 2024-02-01

595
papers

40,205
citations

2795

94
h-index

4323

173
g-index

601
all docs

601
docs citations

601
times ranked

21498
citing authors

#	ARTICLE	IF	CITATIONS
1	Metastatic tumor antigen 1 contributes to hepatocarcinogenesis posttranscriptionally through RNA-binding function. <i>Hepatology</i> , 2023, 77, 379-394.	3.6	3
2	Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBsAg seroconverters. <i>JHEP Reports</i> , 2021, 3, 100254.	2.6	9
3	The epidemiological profile of chronic hepatitis C with advanced hepatic fibrosis regarding virus genotype in Taiwan: A nationwide study. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1444-1451.	0.8	7
4	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 589-597.	1.9	11
5	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. <i>Liver International</i> , 2020, 40, 758-768.	1.9	24
6	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. <i>International Journal of Cancer</i> , 2020, 147, 901-908.	2.3	5
7	Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 167-228.	3.7	320
8	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. <i>Journal of Hepatology</i> , 2020, 72, 839-846.	1.8	49
9	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1345-1352.	1.9	6
10	Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. <i>Advances in Digestive Medicine</i> , 2020, , .	0.1	3
11	HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice. <i>Journal of Biomedical Science</i> , 2020, 27, 70.	2.6	14
12	Hepatitis C virus genotypes 1-3 infections regulate lipogenic signaling and suppress cholesterol biosynthesis in hepatocytes. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1382-1395.	0.8	1
13	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1871-1875.	0.8	5
14	Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer. <i>Hepatology</i> , 2020, 72, 2063-2076.	3.6	34
15	Complement C1q mediates the expansion of periportal hepatic progenitor cells in senescence-associated inflammatory liver. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6717-6725.	3.3	9
16	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1105-1111.	1.8	43
17	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <i>Scientific Reports</i> , 2020, 10, 9180.	1.6	8
18	Taiwan is on track of accelerating hepatitis C elimination by 2025. <i>Liver International</i> , 2020, 40, 1506-1507.	1.9	13

#	ARTICLE	IF	CITATIONS
19	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020, 27, 568-575.	1.0	21
20	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , 2020, 9, 207-220.	4.2	17
21	Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 480-490.	2.3	66
22	Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region. <i>Hepatology</i> , 2019, 69, 498-512.	3.6	40
23	Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 209-221.	3.6	58
24	Taiwan's health-care system and administration are independent of China. <i>Lancet, The</i> , 2019, 394, 1516.	6.3	4
25	Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1187-1192.	0.8	18
26	Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 306-316.	1.9	19
27	High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. <i>Gastroenterology</i> , 2019, 157, 1518-1529.e3.	0.6	83
28	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 589-598.	1.9	29
29	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1620-1625.	1.4	14
30	Lymphocyte Antigen 6 Complex, Locus C+ Monocytes and Kupffer Cells Orchestrate Liver Immune Responses Against Hepatitis B Virus in Mice. <i>Hepatology</i> , 2019, 69, 2364-2380.	3.6	36
31	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2179-2186.	1.4	4
32	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408.	1.8	341
33	Taiwan commits to eliminating hepatitis C in 2025. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 466-467.	4.6	29
34	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-irrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1977-1983.	1.4	7
35	Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 184-197.	3.6	9
36	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 410-417.	1.4	11

#	ARTICLE	IF	CITATIONS
37	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 331-339.	1.9	11
38	Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. <i>Journal of Infectious Diseases</i> , 2018, 217, 1193-1201.	1.9	67
39	Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. <i>Radiology</i> , 2018, 288, 293-299.	3.6	18
40	A noninvasive diagnosis of hepatic fibrosis by BioFibroScore [®] in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 291-297.	1.4	16
41	Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 289-292.	2.9	27
42	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 710-717.	1.4	28
43	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0209299.	1.1	13
44	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Scientific Reports</i> , 2018, 8, 13699.	1.6	22
45	Hepatitis B virus infection. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18035.	18.1	490
46	Chronologic changes in serum hepatitis B virus <scp>DNA</scp>, genotypes, surface antigen mutants and reverse transcriptase mutants during 25-year nationwide immunization in Taiwan. <i>Journal of Viral Hepatitis</i> , 2017, 24, 645-653.	1.0	17
47	De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel BLAST-based assembly pipeline. <i>BMC Bioinformatics</i> , 2017, 18, 223.	1.2	14
48	Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 697-704.	0.8	14
49	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017, 112, 1564-1574.	0.2	44
50	Strategies to manage hepatitis C virus infection disease burden—Volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 44-63.	1.0	17
51	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 25-43.	1.0	26
52	Historical epidemiology of hepatitis C virus in select countries—volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 8-24.	1.0	30
53	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. <i>Scientific Reports</i> , 2017, 7, 1728.	1.6	13
54	Genome-wide association analysis identifies a <i>GLUL</i> haplotype for familial hepatitis B virus-related hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3966-3976.	2.0	23

#	ARTICLE	IF	CITATIONS
55	Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx028.	0.4	43
56	Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. <i>Medicine (United States)</i> , 2016, 95, e2995.	0.4	18
57	Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 286-294.	1.1	42
58	Differences in hepatitis viral etiology of hepatocellular carcinoma in Taiwan and China. <i>Hepatology</i> , 2016, 64, 1008-1009.	3.6	4
59	Hepatitis C viral infection increases the risk of lymphoid neoplasms: A population-based cohort study. <i>Hepatology</i> , 2016, 63, 721-730.	3.6	38
60	Pegylated IFN- λ suppresses hepatitis C virus by promoting the DAPK-mTOR pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 14799-14804.	3.3	10
61	Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 976-985.	0.2	89
62	Continuing Decrease in Hepatitis B Virus Infection 30 Years After Initiation of Infant Vaccination Program in Taiwan. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1324-1330.	2.4	73
63	No more excuses: viral hepatitis can be eliminated. <i>Lancet, The</i> , 2016, 387, 1703-1704.	6.3	14
64	Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11937-11942.	3.3	37
65	Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients. <i>Scientific Reports</i> , 2016, 6, 31349.	1.6	21
66	Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy. <i>Scientific Reports</i> , 2016, 6, 32303.	1.6	11
67	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 953-960.	0.8	6
68	Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. <i>Gastroenterology</i> , 2016, 151, 472-480.e1.	0.6	187
69	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	1.9	1,908
70	Essential components in developing public policy to control viral hepatitis: lessons from Taiwan. <i>Hepatology International</i> , 2016, 10, 355-362.	1.9	3
71	Perspectives on dual hepatitis B and C infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 298-305.	0.8	14
72	Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF- κ B signaling and tumor progression in a woodchuck hepatocellular carcinoma model. <i>Oncotarget</i> , 2016, 7, 47173-47185.	0.8	4

#	ARTICLE	IF	CITATIONS
73	On-Treatment Low Serum HBV RNA Level Predicts Initial Virological Response in Chronic Hepatitis B Patients Receiving Nucleoside Analogue Therapy. <i>Antiviral Therapy</i> , 2015, 20, 369-375.	0.6	61
74	We Have Never Been Latecomers: A Critical Review of High-Tech Industry and Social Studies of Technology in Taiwan. <i>East Asian Science, Technology and Society</i> , 2015, 9, 381-396.	0.2	8
75	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015, 5, 11710.	1.6	7
76	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015, 5, 15255.	1.6	8
77	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. <i>Scientific Reports</i> , 2015, 5, 17410.	1.6	13
78	Microevolution of the hepatitis B virus genome in hepatitis B antigen-positive carriers: Comparison of genotypes B and C at various immune stages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 172-177.	1.4	2
79	Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 902-911.	1.9	46
80	Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2015, 5, 9954.	1.6	53
81	Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. <i>Journal of Hepatology</i> , 2015, 63, 354-363.	1.8	66
82	New Insights into the Evolutionary Rate of Hepatitis B Virus at Different Biological Scales. <i>Journal of Virology</i> , 2015, 89, 3512-3522.	1.5	33
83	Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2175-2180.	3.3	175
84	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015, 64, 303-311.	6.1	39
85	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. <i>Hepatology International</i> , 2015, 9, 35-42.	1.9	12
86	Sorafenib Action in Hepatitis B Virus "Activated Oncogenic Androgen Pathway in Liver through SHP-1. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv190.	3.0	19
87	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7243-7248.	3.3	65
88	From the big three to the big four. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 626-627.	4.6	8
89	Advanced Hepatic Fibrosis and Steatosis Are Associated With Persistent Alanine Aminotransferase Elevation in Chronic Hepatitis C Patients Negative for Hepatitis C Virus RNA During Pegylated Interferon Plus Ribavirin Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 1429-1436.	1.9	7
90	Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. <i>Journal of Hepatology</i> , 2015, 62, S76-S86.	1.8	198

#	ARTICLE	IF	CITATIONS
91	Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1754-1757.	1.8	62
92	Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. <i>Hepatology</i> , 2015, 62, 375-386.	3.6	213
93	Prevention of Hepatitis B. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021493-a021493.	2.9	42
94	Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2015, 9, 231-242.	1.9	25
95	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 949-960.	1.9	49
96	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1200-1209.	1.9	49
97	Feedback regulation of IFN α /IFN β signaling by Axl receptor tyrosine kinase modulates HBV immunity. <i>European Journal of Immunology</i> , 2015, 45, 1696-1705.	1.6	12
98	Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 197-203.	2.8	98
99	Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor α in female hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015, 136, 761-770.	2.3	37
100	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. <i>Gut</i> , 2015, 64, 292-302.	6.1	105
101	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 102-109.	1.4	7
102	Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. <i>Gut</i> , 2014, 63, 1648-1657.	6.1	161
103	The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e186.	2.3	319
104	Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study. <i>Hepatology</i> , 2014, 60, 807-814.	3.6	97
105	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. <i>Liver International</i> , 2014, 34, e71-9.	1.9	14
106	Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: Clinical and mechanistic implications. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1629-1636.	1.4	27
107	Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. <i>Journal of Gastroenterology</i> , 2014, 49, 356-362.	2.3	14
108	Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1242-1249.	1.4	16

#	ARTICLE	IF	CITATIONS
109	A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 716-721.	0.8	8
110	Corrigendum to: "Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia" [Hepatology 2013;59:1073-1080]. <i>Journal of Hepatology</i> , 2014, 60, 902-903.	1.8	0
111	Peginterferon α 2b in the treatment of chronic hepatitis B. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 995-1006.	1.4	18
112	Plasma Adipokines and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus "Infected Carriers: A Prospective Study in Taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1659-1671.	1.1	20
113	Acute rhabdomyolysis and chylous ascites in a patient with cirrhosis and malignant hepatic tumor. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 137-138.	0.8	1
114	Reduced Toll-Like Receptor 9 Expression on Peripheral CD14 ⁺ Monocytes of Chronic Hepatitis B Patients and its Restoration by Effective Therapy. <i>Antiviral Therapy</i> , 2014, 19, 637-643.	0.6	18
115	Multiple variants in UGT1A1 gene are factors to develop indirect hyper-bilirubinemia. <i>Hepatobiliary Surgery and Nutrition</i> , 2014, 3, 194-8.	0.7	7
116	Hepatitis B Virus: Pathogenesis and Host Immune Response. , 2014, , 113-132.		0
117	Biphasic Pattern of Depression and Its Predictors during Pegylated Interferon-Based Therapy in Chronic Hepatitis B and C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-7.	0.6	8
118	Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. <i>Hepatology International</i> , 2013, 7, 171-179.	1.9	6
119	Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. <i>Hepatology International</i> , 2013, 7, 316-326.	1.9	46
120	Cancer prevention in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. <i>Lancet Oncology</i> , The, 2013, 14, e497-e507.	5.1	39
121	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , 2013, 57, 2135-2142.	3.6	66
122	Risk Stratification of Hepatocellular Carcinoma in Hepatitis B Virus e Antigen "Negative Carriers by Combining Viral Biomarkers. <i>Journal of Infectious Diseases</i> , 2013, 208, 584-593.	1.9	45
123	Milder clinical manifestation of scrub typhus in Kinmen, Taiwan. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 201-207.	0.8	22
124	Mother-to-infant transmission of hepatitis B virus infection: Significance of maternal viral load and strategies for intervention. <i>Journal of Hepatology</i> , 2013, 59, 24-30.	1.8	227
125	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013, 57, 934-943.	3.6	47
126	Increased Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients With Newly Diagnosed Diabetes: A Nationwide Cohort Study. <i>Clinical Infectious Diseases</i> , 2013, 57, 1695-1702.	2.9	83

#	ARTICLE	IF	CITATIONS
127	Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. <i>Gut</i> , 2013, 62, 182.2-184.	6.1	67
128	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2332-8.	1.3	17
129	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7844-7849.	3.3	57
130	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. <i>Hepatology</i> , 2013, 57, 441-450.	3.6	227
131	IL-21R Gene Polymorphisms and Serum IL-21 Levels Predict Virological Response to Interferon-Based Therapy in Asian Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-8.	0.6	9
132	Reduced Toll-Like Receptor 3 Expression in Chronic Hepatitis B Patients and Its Restoration by Interferon Therapy. <i>Antiviral Therapy</i> , 2013, 18, 877-884.	0.6	40
133	Pegylated Interferon- α 2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.	2.0	91
134	Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection. <i>PLoS ONE</i> , 2013, 8, e55916.	1.1	19
135	ADAR2-Mediated Editing of miR-214 and miR-122 Precursor and Antisense RNA Transcripts in Liver Cancers. <i>PLoS ONE</i> , 2013, 8, e81922.	1.1	30
136	Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2012, 17, 477-484.	0.6	41
137	Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. <i>Journal of Infectious Diseases</i> , 2012, 206, 1521-1531.	1.9	47
138	Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters. <i>Journal of Infectious Diseases</i> , 2012, 205, 54-63.	1.9	51
139	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1059-1067.	0.6	23
140	Fine mapping of hepatitis B virus preC deletion and its association with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1373-1381.	1.9	31
141	Minimization of hepatitis B infection by a 25-year universal vaccination program. <i>Journal of Hepatology</i> , 2012, 57, 730-735.	1.8	181
142	Estrogen Receptor α Represses Transcription of HBV Genes via Interaction With Hepatocyte Nuclear Factor 4 α . <i>Gastroenterology</i> , 2012, 142, 989-998.e4.	0.6	105
143	High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load. <i>Gastroenterology</i> , 2012, 142, 1140-1149.e3.	0.6	469
144	Towards the eradication of hepatitis B in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2012, 28, 1-9.	0.8	47

#	ARTICLE	IF	CITATIONS
145	Ribavirin Enhances the Action of Interferon- α against Hepatitis C Virus by Promoting the p53 Activity through the ERK1/2 Pathway. <i>PLoS ONE</i> , 2012, 7, e43824.	1.1	13
146	Hepatitis B Virus Nucleocapsid but Not Free Core Antigen Controls Viral Clearance in Mice. <i>Journal of Virology</i> , 2012, 86, 9266-9273.	1.5	23
147	Androgen pathway stimulates MicroRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. <i>Hepatology</i> , 2012, 56, 632-643.	3.6	98
148	Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. <i>Hepatology International</i> , 2012, 6, 598-605.	1.9	2
149	Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 591-597.	1.9	18
150	Impact of hepatitis B virus infection on metabolic profiles and modifying factors. <i>Journal of Viral Hepatitis</i> , 2012, 19, e48-57.	1.0	56
151	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. <i>Hepatology</i> , 2012, 55, 68-76.	3.6	130
152	Treatment of Hepatitis C Virus Infection: Past, Present and Future. , 2012, , 341-371.		0
153	Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. <i>Gastroenterology</i> , 2011, 141, 517-525.e2.	0.6	184
154	Hepatitis B and Deltavirus Infections. , 2011, , 433-440.		0
155	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. <i>Antiviral Therapy</i> , 2011, 16, 227-235.	0.6	5
156	Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon- α -2A Therapy. <i>Antiviral Therapy</i> , 2011, 16, 629-637.	0.6	91
157	The clinical significance of occult hepatitis B transfusion in Taiwan – a look-back study. <i>Transfusion Medicine</i> , 2011, 21, 33-41.	0.5	34
158	Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. <i>Journal of Viral Hepatitis</i> , 2011, 18, e482-e490.	1.0	21
159	Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. <i>Hepatology International</i> , 2011, 5, 814-821.	1.9	13
160	Fighting against viral hepatitis: Lessons from Taiwan. <i>Hepatology</i> , 2011, 54, 381-392.	3.6	61
161	Hepatitis B virus infection, its sequelae, and prevention by vaccination. <i>Current Opinion in Immunology</i> , 2011, 23, 237-243.	2.4	45
162	Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12042-12047.	3.3	117

#	ARTICLE	IF	CITATIONS
163	Reply to Guedj et al.: Early transient increase of hepatitis C virus viral load in genotype 1 and 2 infections, and the use of mathematical modeling. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E303-E303.	3.3	0
164	Taiwan's Antinuclear Movement in the Wake of the Fukushima Disaster, Viewed from an STS Perspective. East Asian Science, Technology and Society, 2011, 5, 567-572.	0.2	4
165	Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1057-1065.	2.2	77
166	Depletion of β -catenin from mature hepatocytes of mice promotes expansion of hepatic progenitor cells and tumor development. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18384-18389.	3.3	33
167	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3719-3724.	3.3	56
168	Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses. PLoS ONE, 2011, 6, e20752.	1.1	18
169	Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antiviral Therapy, 2010, 15, 1133-1139.	0.6	80
170	Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. Antiviral Therapy, 2010, 15, 177-184.	0.6	42
171	Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection. Hepatology International, 2010, 4, 585-593.	1.9	21
172	Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology, 2010, 51, 1547-1554.	3.6	97
173	Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. Genes and Immunity, 2010, 11, 87-93.	2.2	41
174	Clinical manifestations and survival of patients with hepatocellular carcinoma and cardiac metastasis. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 150-155.	1.4	22
175	Toward elimination and eradication of hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 19-25.	1.4	72
176	Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 970-977.	1.4	31
177	Distinct Hepatitis B Virus Dynamics in the Immunotolerant and Early Immunoclearance Phases. Journal of Virology, 2010, 84, 3454-3463.	1.5	81
178	Pegylated Interferon Alfa-2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C. Clinical Infectious Diseases, 2010, 51, 541-549.	2.9	36
179	HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. Journal of Infectious Diseases, 2010, 202, 86-92.	1.9	46
180	Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9340-9345.	3.3	69

#	ARTICLE	IF	CITATIONS
181	Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14769-14774.	3.3	33
182	The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. <i>Kidney International</i> , 2010, 78, 103-109.	2.6	32
183	Recent Advances in the Research of Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Advances in Cancer Research</i> , 2010, 108, 21-72.	1.9	86
184	Hepatitis B vaccination in children: The Taiwan experience. <i>Pathologie Et Biologie</i> , 2010, 58, 296-300.	2.2	80
185	Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1348-1355.	3.0	534
186	Pegylated interferon α -2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. <i>Gut</i> , 2009, 58, 314-316.	6.1	27
187	Glycogen Synthase Kinase-3 Regulates the Phosphorylation of Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein and Viral Replication. <i>Journal of Biological Chemistry</i> , 2009, 284, 5229-5239.	1.6	168
188	Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3 β kinase pathways. <i>Hepatology</i> , 2009, 49, 1515-1524.	3.6	95
189	Both insulin resistance and alanine aminotransferase level increase the risks of cardiovascular disease in fatty liver disease. <i>Hepatology</i> , 2009, 50, 989-989.	3.6	0
190	Identification of androgen response elements in the enhancer I of hepatitis B virus: A mechanism for sex disparity in chronic hepatitis B. <i>Hepatology</i> , 2009, 50, 1392-1402.	3.6	151
191	Human leukocyte antigen ϵ *DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. <i>Journal of Medical Virology</i> , 2009, 81, 588-593.	2.5	6
192	High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2009, 3, 364-370.	1.9	31
193	Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. <i>Hepatology International</i> , 2009, 3, 537-543.	1.9	11
194	Dual chronic hepatitis B virus and hepatitis C virus infection. <i>Hepatology International</i> , 2009, 3, 517-525.	1.9	49
195	Characterization of interleukin 8 in woodchucks with chronic hepatitis B and hepatocellular carcinoma. <i>Genes and Immunity</i> , 2009, 10, 27-36.	2.2	20
196	Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 815-820.	1.4	46
197	Liver Resection Improves the Survival of Patients with Multiple Hepatocellular Carcinomas. <i>Annals of Surgical Oncology</i> , 2009, 16, 848-855.	0.7	105
198	Structure-Based Discovery of Triphenylmethane Derivatives as Inhibitors of Hepatitis C Virus Helicase. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2716-2723.	2.9	55

#	ARTICLE	IF	CITATIONS
199	Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method – Analysis of 2010 Taiwanese patients. <i>European Journal of Cancer</i> , 2009, 45, 1630-1639.	1.3	72
200	Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. <i>Journal of Hepatology</i> , 2009, 50, 805-816.	1.8	216
201	Hepatitis B vaccine and multiple sclerosis: A case of repeated dÃ©jÃ© vu?. <i>Journal of Hepatology</i> , 2009, 51, 598-599.	1.8	0
202	Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy. <i>Digestive and Liver Disease</i> , 2009, 41, 322-323.	0.4	3
203	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.2	34
204	MicroRNA-18a Prevents Estrogen Receptor-Î± Expression, Promoting Proliferation of Hepatocellular Carcinoma Cells. <i>Gastroenterology</i> , 2009, 136, 683-693.	0.6	250
205	Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. <i>Gastroenterology</i> , 2009, 136, 496-504.e3.	0.6	211
206	Hepatitis B Virus Basal Core Promoter Mutation and DNA Load Correlate with Expression of Hepatitis B Core Antigen in Patients with Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2009, 199, 742-749.	1.9	28
207	Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. <i>Antiviral Therapy</i> , 2009, 14, 1157-1163.	0.6	29
208	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.2	6
209	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	0.6	10
210	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	0.6	35
211	Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. <i>Antiviral Therapy</i> , 2009, 14, 203-210.	0.6	12
212	High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. <i>Liver International</i> , 2008, 28, 271-277.	1.9	86
213	Critical analysis of the immune tolerance phase of chronic HBV infection: Natural history and diagnosis. <i>Current Hepatitis Reports</i> , 2008, 7, 5-11.	0.3	3
214	STS and Area Studies: A Social Network Perspective. <i>East Asian Science, Technology and Society</i> , 2008, 2, 439-444.	0.2	0
215	Metabolic profiles in patients with chronic hepatitis C: a case–control study. <i>Hepatology International</i> , 2008, 2, 250-257.	1.9	33
216	A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine–treated chronic hepatitis B patients. <i>Liver International</i> , 2008, 28, 1034-1041.	1.9	19

#	ARTICLE	IF	CITATIONS
217	Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 779-782.	1.4	88
218	Universal Hepatitis B Vaccination: Killing 2 Birds with 1 Stone. <i>American Journal of Medicine</i> , 2008, 121, 1029-1031.	0.6	13
219	Disease Progression in a Patient with Nonalcoholic Steatohepatitis. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 816-821.	0.8	8
220	Pegylated Interferon- α 2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 1260-1269.	2.9	177
221	Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1134-1143.	3.0	549
222	Acute Fatty Liver of Pregnancy with Concurrent Acute Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, 2663-2665.	0.2	0
223	Humoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster 15-18 Years after Neonatal Immunization. <i>Journal of Infectious Diseases</i> , 2008, 197, 1419-1426.	1.9	175
224	Esophageal Varices: Noninvasive Diagnosis with Duplex Doppler US in Patients with Compensated Cirrhosis. <i>Radiology</i> , 2008, 248, 132-139.	3.6	29
225	Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis. <i>Antiviral Therapy</i> , 2008, 13, 469-80.	0.6	3
226	Hepatitis B virus Quantification and Detection of YMDD Mutants in a Single Reaction by Real-Time PCR and Annealing Curve Analysis. <i>Antiviral Therapy</i> , 2008, 13, 469-480.	0.6	8
227	Pegylated interferon α -2a versus standard interferon α -2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. <i>Gut</i> , 2007, 57, 525-530.	6.1	69
228	Taiwan as a Clinical Trial Center of Excellence in the Asia Pacific. <i>Asia Pacific Biotech News</i> , 2007, 11, 841-844.	0.5	0
229	OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. <i>Nucleic Acids Research</i> , 2007, 35, D727-D731.	6.5	99
230	Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 2571-2578.	3.3	126
231	Ribavirin Upregulates the Activity of Double-Stranded RNA-Activated Protein Kinase and Enhances the Action of Interferon- α against Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2007, 196, 425-434.	1.9	47
232	Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan. <i>Intervirology</i> , 2007, 50, 310-315.	1.2	17
233	Two Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies. <i>Gastroenterology</i> , 2007, 132, 1287-1293.	0.6	314
234	Noninvasive Diagnosis of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler Impedance Index. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1199-1206.e1.	2.4	29

#	ARTICLE	IF	CITATIONS
235	Viremia Profiles in Children With Chronic Hepatitis B Virus Infection and Spontaneous e Antigen Seroconversion. <i>Gastroenterology</i> , 2007, 132, 2340-2345.	0.6	72
236	Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2007, 120, 1610-1617.	2.3	21
237	APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: More questions than answers. <i>Hepatology</i> , 2007, 45, 1586-1587.	3.6	0
238	Hepatitis B viral factors in HBeAg-Negative carriers with persistently normal serum alanine aminotransferase levels. <i>Hepatology</i> , 2007, 45, 1193-1198.	3.6	103
239	High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. <i>Journal of Medical Virology</i> , 2007, 79, 1674-1678.	2.5	25
240	Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1098-1103.	1.4	76
241	Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 64-69.	1.0	22
242	Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 153-160.	1.0	16
243	Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. <i>Liver International</i> , 2007, 27, 235-239.	1.9	7
244	Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan. <i>Liver International</i> , 2007, 27, 983-988.	1.9	14
245	Hepatocellular carcinoma in Taiwan. <i>Hepatology Research</i> , 2007, 37, S101-5.	1.8	79
246	Characterization of cytokeratin 19-positive hepatocyte foci in the regenerating rat liver after 2-AAF/CCl4 injury. <i>Histochemistry and Cell Biology</i> , 2007, 128, 217-226.	0.8	11
247	Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NAT. <i>Journal of Clinical Virology</i> , 2006, 36, S33-S44.	1.6	105
248	Natural Course and Treatment of Hepatitis D Virus Infection. <i>Journal of the Formosan Medical Association</i> , 2006, 105, 869-881.	0.8	39
249	High Prevalence and Mapping of Pre-S Deletion in Hepatitis B Virus Carriers With Progressive Liver Diseases. <i>Gastroenterology</i> , 2006, 130, 1153-1168.	0.6	257
250	Kinetics of Hepatitis B Virus Reactivation After Chemotherapy: More Questions Than Answers. <i>Gastroenterology</i> , 2006, 131, 1656.	0.6	9
251	Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma.. <i>Clinical Cancer Research</i> , 2006, 12, 1097-1108.	3.2	52
252	Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. <i>European Journal of Cancer</i> , 2006, 42, 2524-2529.	1.3	67

#	ARTICLE	IF	CITATIONS
253	Genetic predisposition of responsiveness to therapy for chronic hepatitis C. <i>Pharmacogenomics</i> , 2006, 7, 697-709.	0.6	31
254	Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. <i>Journal of Hepatology</i> , 2006, 44, 39-46.	1.8	105
255	Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. <i>Proteomics</i> , 2006, 6, 2865-2873.	1.3	109
256	Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristics. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 605-609.	1.4	58
257	Higher cut-off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 859-862.	1.4	16
258	Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: Analysis of 11 312 patients in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1561-1566.	1.4	56
259	Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. <i>Liver International</i> , 2006, 26, 766-773.	1.9	65
260	Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. <i>Liver International</i> , 2006, 26, 949-955.	1.9	40
261	Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. <i>Liver International</i> , 2006, 26, 1087-1094.	1.9	55
262	Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. <i>Journal of Viral Hepatitis</i> , 2006, 13, 387-395.	1.0	14
263	Reactivation of Hepatitis B Virus in Rheumatologic Patients Receiving Immunosuppressive Agents. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1627-1632.	1.1	24
264	HBV genotypes: Epidemiology and implications regarding natural history. <i>Current Hepatitis Reports</i> , 2006, 5, 5-13.	0.3	35
265	Local ablation vs. resection for the treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2006, 43, 373-373.	3.6	34
266	Interferon α -2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study. <i>Hepatology</i> , 2006, 43, 742-749.	3.6	41
267	Mixed hepatitis B virus genotype infections: The more, the worse?. <i>Hepatology</i> , 2006, 44, 770-770.	3.6	8
268	Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. <i>International Journal of Cancer</i> , 2006, 119, 1946-1952.	2.3	120
269	Prospect of Individualized Medicine in Chronic Hepatitis C Therapy by Pharmacogenomics. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2006, 4, 157-167.	0.3	3
270	Role of Hepatitis B Virus Precore/Core Promoter Mutations and Serum Viral Load on Noncirrhotic Hepatocellular Carcinoma: A Case-Control Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 594-599.	1.9	125

#	ARTICLE	IF	CITATIONS
271	Clinical Significance of Occult Hepatitis B Virus Infection Cannot Be Overlooked. <i>Clinical Infectious Diseases</i> , 2006, 42, 583-584.	2.9	2
272	Role of Hepatitis B Viral Load and Basal Core Promoter Mutation in Hepatocellular Carcinoma in Hepatitis B Carriers. <i>Journal of Infectious Diseases</i> , 2006, 193, 1258-1265.	1.9	163
273	Comparative Immunoproteomics of Identification and Characterization of Virulence Factors from <i>Helicobacter pylori</i> Related to Gastric Cancer. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1484-1496.	2.5	60
274	Evolution of Hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. <i>Journal of General Virology</i> , 2006, 87, 39-49.	1.3	30
275	An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17862-17867.	3.3	265
276	Selective Transmission of Hepatitis C Virus Quasi Species through a Needlestick Accident in Acute Resolving Hepatitis. <i>Clinical Infectious Diseases</i> , 2006, 42, 1254-1259.	2.9	12
277	Percutaneous Ethanol Injection Versus Surgical Resection for the Treatment of Small Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2005, 242, 36-42.	2.1	180
278	Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. <i>Liver International</i> , 2005, 25, 564-570.	1.9	68
279	Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. <i>Liver International</i> , 2005, 25, 214-219.	1.9	21
280	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. <i>Liver International</i> , 2005, 25, 472-489.	1.9	313
281	Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. <i>Liver International</i> , 2005, 25, 696-703.	1.9	98
282	Therapeutic implications of hepatitis B virus genotypes. <i>Liver International</i> , 2005, 25, 1097-1107.	1.9	100
283	Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11. <i>Genes Chromosomes and Cancer</i> , 2005, 44, 320-328.	1.5	29
284	HBV genotypes and outcome of HBV infection. <i>Hepatology</i> , 2005, 41, 216-216.	3.6	7
285	Epigenetic activation of β 4, β 2 and β 6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. <i>Journal of Biomedical Science</i> , 2005, 12, 803-813.	2.6	19
286	Long-Term Protection of Hepatitis B Vaccine: Lessons from Alaskan Experience after 15 Years. <i>Annals of Internal Medicine</i> , 2005, 142, 384.	2.0	20
287	Application of Hepatitis B Virus Genotyping and Phylogenetic Analysis in Intrafamilial Transmission of Hepatitis B Virus. <i>Clinical Infectious Diseases</i> , 2005, 41, 1576-1581.	2.9	39
288	Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men. <i>Journal of the National Cancer Institute</i> , 2005, 97, 265-272.	3.0	518

#	ARTICLE	IF	CITATIONS
289	Caput Medusae. <i>New England Journal of Medicine</i> , 2005, 353, e19.	13.9	7
290	Prevention of Hepatocellular Carcinoma by Universal Vaccination against Hepatitis B Virus: The Effect and Problems. <i>Clinical Cancer Research</i> , 2005, 11, 7953-7957.	3.2	153
291	Hepatitis B vaccination: to boost or not to boost?. <i>Lancet, The</i> , 2005, 366, 1337-1338.	6.3	44
292	Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 235-242.	1.8	64
293	RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. <i>Gastroenterology</i> , 2005, 128, 708-716.	0.6	97
294	Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-15.	0.6	6
295	Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. <i>Journal of the Formosan Medical Association</i> , 2005, 104, 783-91.	0.8	38
296	Influence of Metabolic Syndrome, Viral Genotype and Antiviral Therapy on Superimposed Fatty Liver Disease in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-415.	0.6	30
297	Epidemiologic Features of Kawasaki Disease in Taiwan, 1996-2002. <i>Pediatrics</i> , 2004, 114, e678-e682.	1.0	76
298	Clustering of Minimal Deleted Regions Reveals Distinct Genetic Pathways of Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2004, 64, 3030-3036.	0.4	38
299	Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: Molecular epidemiology and genome evolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2542-2547.	3.3	121
300	Role of zinc in subclinical hepatic encephalopathy: Comparison with somatosensory-evoked potentials. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 375-379.	1.4	16
301	Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy. <i>Liver International</i> , 2004, 24, 9-15.	1.9	14
302	The small delta antigen of hepatitis delta virus is an acetylated protein and acetylation of lysine 72 may influence its cellular localization and viral RNA synthesis. <i>Virology</i> , 2004, 319, 60-70.	1.1	59
303	Curative potential of GM-CSF-secreting tumor cell vaccines on established orthotopic liver tumors: Mechanisms for the superior antitumor activity of live tumor cell vaccines. <i>Journal of Biomedical Science</i> , 2004, 11, 228-238.	2.6	14
304	Allelic loss of chromosome 4q21-23 associates with hepatitis B Virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. <i>Hepatology</i> , 2004, 40, 847-854.	3.6	6
305	Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. <i>Hepatology</i> , 2004, 39, 58-63.	3.6	114
306	A forgotten population with chronic hepatitis C infection: Subjects coinfecting with hepatitis B virus. <i>Hepatology</i> , 2004, 40, 266-266.	3.6	12

#	ARTICLE	IF	CITATIONS
307	Origin of serum hepatitis B virus in acute exacerbation: Comparison with HBV in the liver and from other exacerbation. <i>Hepatology</i> , 2004, 40, 310-317.	3.6	22
308	Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. <i>Journal of Medical Virology</i> , 2004, 72, 363-369.	2.5	159
309	Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis. <i>Journal of Medical Virology</i> , 2004, 72, 545-550.	2.5	42
310	Genotypic dominance and novel recombinations in HBV genotype B and C co-infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 73, 13-22.	2.5	43
311	Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. <i>Journal of Medical Virology</i> , 2004, 74, 237-245.	2.5	23
312	High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 74, 536-542.	2.5	40
313	Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 64-71.	2.4	50
314	Hepatitis B virus genotypes and core promoter variant. <i>Gastroenterology</i> , 2004, 126, 633.	0.6	1
315	Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. <i>Gastroenterology</i> , 2004, 127, 1733-1738.	0.6	197
316	Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2004, 315, 950-958.	1.0	143
317	Hepatitis C virus NS3 RNA helicase activity is modulated by the two domains of NS3 and NS4A. <i>Biochemical and Biophysical Research Communications</i> , 2004, 317, 211-217.	1.0	39
318	Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 40, 653-659.	1.8	45
319	Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. <i>Journal of Hepatology</i> , 2004, 41, 659-666.	1.8	194
320	Allelic loss of chromosome 4q21?23 associates with hepatitis B virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. <i>Hepatology</i> , 2004, 40, 847-854.	3.6	24
321	End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2004, 10, 3574.	1.4	14
322	Lack of Interferon Sensitivity-Determining Region in the Genome of Hepatitis B Virus Genotype Ba. <i>Antiviral Therapy</i> , 2004, 9, 895-903.	0.6	10
323	Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. <i>Hepatology</i> , 2003, 37, 568-576.	3.6	111
324	Molecular assays for hepatitis B virus infection. <i>Hepatology</i> , 2003, 38, 1311-1311.	3.6	6

#	ARTICLE	IF	CITATIONS
325	An oath for bioscientists. <i>Journal of Biomedical Science</i> , 2003, 10, 569-576.	2.6	1
326	Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. <i>Journal of Medical Virology</i> , 2003, 69, 466-470.	2.5	50
327	Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors. <i>Journal of Gene Medicine</i> , 2003, 5, 386-398.	1.4	25
328	Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. <i>Liver International</i> , 2003, 23, 148-155.	1.9	20
329	Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. <i>Liver International</i> , 2003, 23, 426-433.	1.9	19
330	A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. <i>Gastroenterology</i> , 2003, 124, 80-90.	0.6	68
331	Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. <i>Gastroenterology</i> , 2003, 124, 327-334.	0.6	499
332	Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan. <i>Gastroenterology</i> , 2003, 125, 1916-1917.	0.6	20
333	Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. <i>Journal of Hepatology</i> , 2003, 39, 1028-1035.	1.8	17
334	Long-term Immunogenicity and Efficacy of Universal Hepatitis B Virus Vaccination in Taiwan. <i>Journal of Infectious Diseases</i> , 2003, 187, 134-138.	1.9	134
335	A prospect for pharmacogenomics in the interferon therapy of chronic viral hepatitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 149-151.	1.3	6
336	SEN Virus Infection in Patients with Chronic Hepatitis C: Preferential Coinfection with Hepatitis C Genotype 2a and No Effect on Response to Therapy with Interferon plus Ribavirin. <i>Journal of Infectious Diseases</i> , 2003, 187, 307-310.	1.9	20
337	An oath for bioscientists. <i>Journal of Biomedical Science</i> , 2003, 10, 569-76.	2.6	1
338	A Hospital-Based Study on the use of Alternative Medicine in Patients with Chronic Liver and Gastrointestinal Diseases. <i>The American Journal of Chinese Medicine</i> , 2002, 30, 637-643.	1.5	33
339	The Double-stranded RNA-activated Kinase, PKR, Can Phosphorylate Hepatitis D Virus Small Delta Antigen at Functional Serine and Threonine Residues. <i>Journal of Biological Chemistry</i> , 2002, 277, 33058-33067.	1.6	38
340	Hepatitis D Virus Genotypes in Intravenous Drug Users in Taiwan: Decreasing Prevalence and Lack of Correlation with Hepatitis B Virus Genotypes. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3047-3049.	1.8	37
341	Prevalence and Implication of a Newly Identified Infectious Agent (SEN Virus) in Taiwan. <i>Journal of Infectious Diseases</i> , 2002, 185, 389-392.	1.9	48
342	Genotypes and Clinical Phenotypes of Hepatitis B Virus in Patients with Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1207-1209.	1.8	178

#	ARTICLE	IF	CITATIONS
343	Occult Hepatitis B Virus Infection and Clinical Outcomes of Patients with Chronic Hepatitis C. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4068-4071.	1.8	149
344	Clinical and Virological Aspects of Blood Donors Infected with Hepatitis B Virus Genotypes B and C. <i>Journal of Clinical Microbiology</i> , 2002, 40, 22-25.	1.8	83
345	Prevention of hepatocellular carcinoma by hepatitis B immunization. <i>Perspectives in Medical Virology</i> , 2002, 6, 143-150.	0.1	0
346	Hepatitis B viral genotypes and lamivudine resistance. <i>Journal of Hepatology</i> , 2002, 36, 303-304.	1.8	102
347	Global control of hepatitis B virus infection. <i>Lancet Infectious Diseases</i> , The, 2002, 2, 395-403.	4.6	750
348	Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2002, 347, 168-174.	13.9	1,170
349	Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: Correlation with viral serotypes and clinical stages of liver disease. <i>Journal of Medical Virology</i> , 2002, 68, 50-59.	2.5	40
350	Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. <i>Journal of Medical Virology</i> , 2002, 68, 216-220.	2.5	39
351	Early acquisition of TT virus in infants: Possible minor role of maternal transmission. <i>Journal of Medical Virology</i> , 2002, 66, 285-290.	2.5	24
352	Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: Role of dendritic cells. <i>Journal of Medical Virology</i> , 2002, 66, 320-328.	2.5	40
353	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	3.6	30
354	Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2002, 97, 269-271.	2.3	18
355	Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2002, 37, 283-287.	2.3	39
356	Decreasing serum alpha-fetoprotein levels in predicting poor prognosis of acute hepatic failure in patients with chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2002, 37, 626-632.	2.3	43
357	Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. <i>Transfusion</i> , 2002, 42, 1592-1597.	0.8	76
358	Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 352-357.	1.4	15
359	Comparison of two methods for quantification of hepatitis B viral DNA. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 423-426.	1.4	16
360	Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: Role of viral infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 682-689.	1.4	24

#	ARTICLE	IF	CITATIONS
361	Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: Multistage hepatocarcinogenesis with multifactorial etiology. <i>Hepatology</i> , 2002, 36, 1046-1049.	3.6	111
362	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	3.6	41
363	Recent research progress in hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2002, 101, 239-48.	0.8	13
364	Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis. <i>Cancer Research</i> , 2002, 62, 4346-51.	0.4	22
365	Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. <i>Journal of Pediatrics</i> , 2001, 139, 349-352.	0.9	99
366	Efficacy of a mass hepatitis B immunization program after switching to recombinant hepatitis B vaccine: a population-based study in Taiwan. <i>Vaccine</i> , 2001, 19, 2825-2829.	1.7	21
367	Mother-to-child HCV transmission. <i>Lancet, The</i> , 2001, 357, 142-143.	6.3	5
368	Expressions of cancer-testis antigens in human hepatocellular carcinomas. <i>Cancer Letters</i> , 2001, 164, 189-195.	3.2	52
369	Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination. <i>Annals of Internal Medicine</i> , 2001, 135, 796.	2.0	311
370	Amebic Liver Abscess and Human Immunodeficiency Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2001, 33, 64-68.	1.1	27
371	Ribavirin enhances interferon- β levels in patients with chronic hepatitis C treated with interferon- α . <i>Journal of Biomedical Science</i> , 2001, 8, 484-491.	2.6	7
372	Post-partum acute exacerbation of chronic hepatitis in a hepatitis C-carrier mother. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 705-708.	1.4	13
373	Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: A 4-year experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 1001-1008.	1.4	40
374	Molecular cloning and expression of woodchuck granulocyte-macrophage colony stimulating factor. <i>Journal of Medical Virology</i> , 2001, 65, 567-575.	2.5	9
375	Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. <i>Hepatology</i> , 2001, 34, 583-589.	3.6	50
376	Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. <i>Hepatology</i> , 2001, 34, 817-823.	3.6	73
377	Ribavirin Enhances Interferon- γ Levels in Patients with Chronic Hepatitis C Treated with Interferon- α . <i>Journal of Biomedical Science</i> , 2001, 8, 484-491.	2.6	14
378	The Conserved Serine 177 in the Delta Antigen of Hepatitis Delta Virus Is One Putative Phosphorylation Site and Is Required for Efficient Viral RNA Replication. <i>Journal of Virology</i> , 2001, 75, 9087-9095.	1.5	40

#	ARTICLE	IF	CITATIONS
379	Structure-Based Mutational Analysis of the Hepatitis C Virus NS3 Helicase. <i>Journal of Virology</i> , 2001, 75, 8289-8297.	1.5	65
380	Functional Measurement of Hepatitis C Virus Core-Specific CD8 + T-Cell Responses in the Livers or Peripheral Blood of Patients by Using Autologous Peripheral Blood Mononuclear Cells as Targets or Stimulators. <i>Journal of Clinical Microbiology</i> , 2001, 39, 3895-3901.	1.8	6
381	TT virus infection in patients with chronic hepatitis B or C: Influence on clinical, histological and virological features. , 2000, 60, 387-392.		28
382	Low incidence of hepatitis C virus transmission between spouses: A prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 391-395.	1.4	51
383	Efficacy of consensus interferon in the treatment of chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1418-1423.	1.4	11
384	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1287-1291.	1.4	0
385	Tumor-Induced Immunosuppression: A Barrier to Immunotherapy of Large Tumors by Cytokine-Secreting Tumor Vaccine. <i>Human Gene Therapy</i> , 2000, 11, 681-692.	1.4	62
386	Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2000, 118, 554-559.	0.6	892
387	Hepatitis B genotypes and the response to interferon therapy. <i>Journal of Hepatology</i> , 2000, 33, 998-1002.	1.8	449
388	Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. <i>Journal of Hepatology</i> , 2000, 33, 791-798.	1.8	87
389	Public health measures to control hepatitis B virus infection in the developing countries of the Asia-Pacific region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, E7-E10.	1.4	24
390	Transmission of hepatitis C virus in Asia: past and present perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, E91-E96.	1.4	69
391	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1287-1291.	1.4	0
392	Hepatitis B Virus Infection and Hepatocellular Carcinoma: Molecular Genetics and Clinical Perspectives. <i>Seminars in Liver Disease</i> , 1999, 19, 253-262.	1.8	75
393	High frequency of expression of MAGE genes in human hepatocellular carcinoma. <i>Liver International</i> , 1999, 19, 110-114.	1.9	31
394	Prospects for hepatitis B virus eradication and control of hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 1999, 13, 511-517.	1.0	14
395	GB virus-C/hepatitis G virus infection in Taiwan: A virus that fails to cause a disease?. <i>Journal of Biomedical Science</i> , 1999, 6, 220-225.	2.6	12
396	Liver and peripheral blood mononuclear cells are not major sites for GB virus-C/hepatitis G virus replication. <i>Archives of Virology</i> , 1999, 144, 2173-2183.	0.9	11

#	ARTICLE	IF	CITATIONS
397	Characterization of monoclonal antibodies against hepatitis C virus nonstructural protein 3: Different antigenic determinants from human B cells. , 1999, 57, 345-350.		7
398	Prevalence and implication of TT virus infection: Minimal role in patients with non-A-E hepatitis in Taiwan. , 1999, 59, 307-312.		42
399	Molecular methods of measurement of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection: implications for occupational health practice. Occupational and Environmental Medicine, 1999, 56, 730-734.	1.3	9
400	Hepatitis A vaccine in healthy adults: a comparison of immunogenicity and reactogenicity between two- and three-dose regimens. Vaccine, 1999, 17, 26-30.	1.7	11
401	Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. Pediatric Infectious Disease Journal, 1999, 18, 427-432.	1.1	38
402	Characterization of the Phosphorylated Forms and the Phosphorylated Residues of Hepatitis Delta Virus Delta Antigens. Journal of Virology, 1999, 73, 10540-10545.	1.5	36
403	GB virus-C/hepatitis G virus infection in Taiwan: A virus that fails to cause a disease?. , 1999, 6, 220.		1
404	Characteristics of hepatocellular carcinoma presenting with variceal bleeding. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 170-174.	1.4	18
405	Somatosensory evoked potentials in subclinical portosystemic encephalopathy: A comparison with psychometric tests. Hepatology, 1998, 27, 357-361.	3.6	46
406	Effects of GB virus-C/hepatitis G virus on hepatitis B and C viremia in multiple hepatitis virus infections. Archives of Virology, 1998, 143, 797-802.	0.9	13
407	Hepatocyte growth factor stimulates the growth and activates mitogen-activated protein kinase in human hepatoma cells. Journal of Biomedical Science, 1998, 5, 180-184.	2.6	20
408	Establishment and characterization of NS3 protein-specific T-cell clones from a patient with chronic hepatitis C. Journal of Biomedical Science, 1998, 5, 290-296.	2.6	9
409	Long-term culture of hepatocytes from human adults. Journal of Biomedical Science, 1998, 5, 435-440.	2.6	35
410	Icteric type hepatocellular carcinoma: Revisited 20 years later. Journal of Gastroenterology, 1998, 33, 53-56.	2.3	44
411	BRIEF COMMUNICATION: Efficacy of ribavirin plus interferon alpha on viraemia of GB virus-C/hepatitis G virus: Comparison with interferon alpha alone. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 1249-1253.	1.4	8
412	Antibodies to E2 protein of hepatitis G virus in children: Different responses according to age at infection. Journal of Pediatrics, 1998, 133, 382-385.	0.9	21
413	Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen. Journal of Hepatology, 1998, 28, 915-922.	1.8	59
414	An ELISA for RNA Helicase Activity: Application as an Assay of the NS3 Helicase of Hepatitis C Virus. Biochemical and Biophysical Research Communications, 1998, 253, 594-599.	1.0	29

#	ARTICLE	IF	CITATIONS
415	Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. <i>Biochemical Pharmacology</i> , 1998, 55, 523-531.	2.0	54
416	Clinical Impact of Screening First-Degree Relatives of Patients with Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 1998, 27, 236-239.	1.1	20
417	A Defective Interference-Like Phenomenon of Human Hepatitis B Virus in Chronic Carriers. <i>Journal of Virology</i> , 1998, 72, 578-584.	1.5	59
418	Hepatocyte growth factor stimulates the growth and activates mitogen-activated protein kinase in human hepatoma cells. , 1998, 5, 180.		3
419	Establishment and characterization of NS3 protein-specific T-cell clones from a patient with chronic hepatitis C. , 1998, 5, 290.		1
420	Regression of Established Mouse Leukemia by GM-CSF-Transduced Tumor Vaccine: Implications for Cytotoxic T Lymphocyte Responses and Tumor Burdens. <i>Human Gene Therapy</i> , 1997, 8, 1843-1854.	1.4	32
421	Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children. <i>New England Journal of Medicine</i> , 1997, 336, 1855-1859.	13.9	1,724
422	Reply to de Sio et al.. <i>Journal of Hepatology</i> , 1997, 26, 1156.	1.8	0
423	CASE REPORT: Successful palliative treatment with intraperitoneal OK-432 injection for epithelioid haemangioendothelioma presenting with intractable ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 39-43.	1.4	3
424	Molecular biology of hepatitis D virus: Research and potential for application. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, S188-S192.	1.4	16
425	Assembly of Hepatitis Delta Virus-like Empty Particles in Yeast. <i>Virology</i> , 1997, 236, 374-381.	1.1	11
426	Identification of the Functional Regions Required for Hepatitis D Virus Replication and Transcription by Linker-Scanning Mutagenesis of Viral Genome. <i>Virology</i> , 1997, 239, 119-131.	1.1	32
427	Inhibition of hepatitis delta virus genomic ribozyme self-cleavage by aminoglycosides. <i>Journal of Biomedical Science</i> , 1997, 4, 208-216.	2.6	37
428	Interspousal transmission of GB virus-C/hepatitis G virus: A comparison with hepatitis C virus. <i>Journal of Medical Virology</i> , 1997, 53, 348-353.	2.5	31
429	Bile Duct Hamartomas. <i>Journal of Clinical Gastroenterology</i> , 1997, 25, 608-611.	1.1	40
430	Least microtransfusion from mother to fetus in elective cesarean delivery. <i>Obstetrics and Gynecology</i> , 1996, 87, 244-248.	1.2	60
431	GBV-C/HGV infection and aplastic anaemia. <i>Lancet, The</i> , 1996, 348, 1032-1033.	6.3	11
432	GBV-C in the aetiology of fulminant hepatitis. <i>Lancet, The</i> , 1996, 347, 120-121.	6.3	83

#	ARTICLE	IF	CITATIONS
433	Mechanism of vertical transmission of hepatitis G. <i>Lancet, The</i> , 1996, 347, 1116.	6.3	30
434	Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma – a study based on 420 patients. <i>Journal of Hepatology</i> , 1996, 25, 334-338.	1.8	138
435	Surgical resection for recurrent hepatocellular carcinoma: Prognosis and analysis of risk factors. <i>Surgery</i> , 1996, 120, 23-29.	1.0	88
436	Alcoholism, Hepatitis B and C Viral Infections, and Impaired Liver Function among Taiwanese Aboriginal Groups. <i>American Journal of Epidemiology</i> , 1996, 143, 936-942.	1.6	16
437	Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. <i>Digestive Diseases and Sciences</i> , 1996, 41, 161-165.	1.1	58
438	Chromosome 1p aberrations are frequent in human primary hepatocellular carcinoma. <i>Cancer Genetics and Cytogenetics</i> , 1996, 86, 102-106.	1.0	35
439	N-Linked Glycosylation of Hepatitis B Surface Antigens Is Involved but Not Essential in the Assembly of Hepatitis Delta Virus. <i>Virology</i> , 1996, 220, 28-36.	1.1	26
440	Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: Correlation with genotypes. <i>Journal of Gastroenterology</i> , 1996, 31, 224-227.	2.3	18
441	Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. , 1996, 77, 872-877.		30
442	A program for eradication of hepatitis B from Taiwan by a 10-year, four-dose vaccination program. <i>Cancer Causes and Control</i> , 1996, 7, 305-311.	0.8	16
443	Identification of Humoral Antigenic Determinants in the Hepatitis C Virus NS3 Protein. <i>Journal of Infectious Diseases</i> , 1996, 174, 173-176.	1.9	14
444	Phylogenetic Analysis of GB Virus C: Comparison of Isolates from Africa, North America, and Taiwan. <i>Journal of Infectious Diseases</i> , 1996, 174, 410-413.	1.9	54
445	Rapid hepatic failure associated with a contracted liver mimicking cirrhosis in a case of nasopharyngeal carcinoma with liver metastasis. <i>Liver</i> , 1996, 16, 283-287.	0.1	10
446	Serum Hepatitis C Virus Titers in the Progression of Type C Chronic Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 280-283.	1.1	8
447	Hepatitis C Viral Infection in Thalassemic Children: Clinical and Molecular Studies. <i>Pediatric Research</i> , 1996, 39, 323-328.	1.1	21
448	Genotypes of Hepatitis C Virus in Taiwan and the Progression of Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 233-237.	1.1	50
449	Intrafamilial transmission of hepatitis C virus in hemodialysis patients. <i>Journal of Medical Virology</i> , 1995, 45, 381-385.	2.5	36
450	The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of age. <i>Hepatology</i> , 1995, 22, 1387-1392.	3.6	108

#	ARTICLE	IF	CITATIONS
451	Quantitative detection of hepatitis B virus DNA in human sera by branched-DNA signal amplification. <i>Journal of Virological Methods</i> , 1995, 53, 131-137.	1.0	22
452	Long-Term Expression of the Biologically Active Growth Hormone in Genetically Modified Fibroblasts after Implantation into a Hypophysectomized Rat. <i>Human Gene Therapy</i> , 1995, 6, 917-926.	1.4	24
453	Early Interferon Therapy and Abortion of Posttransfusion Hepatitis C Viral Infection. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 38-41.	1.1	4
454	Prominent proliferative response of peripheral blood mononuclear cells to a recombinant non-structural (NS3) protein of hepatitis C virus in patients with chronic hepatitis C. <i>Clinical and Experimental Immunology</i> , 1995, 101, 272-277.	1.1	11
455	Quasispecies of Hepatitis C Virus and Genetic Drift of the Hypervariable Region in Chronic Type C Hepatitis. <i>Journal of Infectious Diseases</i> , 1995, 172, 261-264.	1.9	53
456	Prevalence, Genotypes and Antibody Titer of Hepatitis C Virus in Pregnant Women in Taiwan. <i>Journal of Obstetrics and Gynaecology (Tokyo, Japan)</i> , 1995, 21, 557-562.	0.1	4
457	The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of age*1. <i>Hepatology</i> , 1995, 22, 1387-1392.	3.6	10
458	Evaluation of Third-Generation Hepatitis C Antibody Assay in Chronic Hepatitis C and Chronic Non-B, Non-C Hepatitis. <i>Viral Immunology</i> , 1995, 8, 135-139.	0.6	2
459	Title is missing!. <i>Journal of Pediatrics</i> , 1995, 127, 671.	0.9	1
460	Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. <i>Journal of Pediatrics</i> , 1995, 126, 589-591.	0.9	188
461	Portal blood flow in acute hepatitis with and without ascites: A non-invasive measurement using an ultrasonic Doppler. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1995, 10, 36-41.	1.4	16
462	Effect of hepatitis C antibody screening in blood donors on post-transfusion hepatitis in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1995, 10, 454-458.	1.4	21
463	Detection of Divergent Hepatitis C Virus Envelope Sequences. <i>Journal of Biomedical Science</i> , 1994, 1, 158-162.	2.6	0
464	Possible Role of High-Titer Maternal Viremia in Perinatal Transmission of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 1994, 169, 638-641.	1.9	163
465	Mixed Infections Of Hepatitis C Virus As A Factor In Acute Exacerbations Of Chronic Type C Hepatitis. <i>Journal of Infectious Diseases</i> , 1994, 170, 1128-1133.	1.9	71
466	Genotypes of hepatitis C virus in chronic liver disease in Taiwan. <i>Journal of Medical Virology</i> , 1994, 44, 234-236.	2.5	34
467	Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. A study of 150 patients. <i>Cancer</i> , 1994, 73, 42-47.	2.0	52
468	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994, 19, 1321-1324.	3.6	962

#	ARTICLE	IF	CITATIONS
469	Isoprenylation of Large Hepatitis Delta Antigen Is Necessary but Not Sufficient for Hepatitis Delta Virus Assembly. <i>Virology</i> , 1994, 199, 169-175.	1.1	76
470	Detection of divergent hepatitis C virus envelope sequences. <i>Journal of Biomedical Science</i> , 1994, 1, 158-162.	2.6	3
471	Characterization of T cell clones specific to a determinant of hepatitis B virus core and e antigens in chronic type B hepatitis: Implication for a T cell mechanism of HBV immunopathogenesis. <i>Journal of Biomedical Science</i> , 1994, 1, 105-118.	2.6	8
472	Inverse polymerase chain reaction for cloning cellular sequences adjacent to integrated hepatitis B virus DNA in hepatocellular carcinomas. <i>Journal of Virological Methods</i> , 1994, 49, 269-284.	1.0	30
473	Immune response to a hepatitis C virus nonstructural protein in chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 1994, 21, 403-411.	1.8	26
474	Temporal profile of hepatitis C virus antibody and genome in infants born to mothers infected with hepatitis C virus but without human immunodeficiency virus coinfection. <i>Journal of Hepatology</i> , 1994, 20, 641-645.	1.8	49
475	A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. <i>Journal of Hepatology</i> , 1994, 21, 244-249.	1.8	36
476	Posttransfusion hepatitis C virus infection in children. <i>Journal of Pediatrics</i> , 1994, 124, 709-713.	0.9	49
477	Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. <i>Gastroenterology</i> , 1994, 107, 1514-1518.	0.6	86
478	Albumin messenger RNA is not specific for circulating hepatoma cells. <i>Gastroenterology</i> , 1994, 107, 630-631.	0.6	27
479	Characterization of T Cell Clones Specific to a Determinant of Hepatitis B Virus Core and e Antigens in Chronic Type B Hepatitis: Implication for a T Cell Mechanism of HBV Immunopathogenesis. <i>Journal of Biomedical Science</i> , 1994, 1, 105-118.	2.6	2
480	Long term clinical and virologic outcome of primary hepatitis C virus infection in children. <i>Pediatric Infectious Disease Journal</i> , 1994, 13, 769-773.	1.1	40
481	Hepatitis C Virus Infection in Pregnant Women: Detection by Different Anti-HCV Immunoassays and Serum HCV-RNA. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1994, 20, 13-18.	0.0	2
482	Age-specific Prevalence of Hepatitis B Surface and e Antigenemia in Pregnant Women in Taiwan. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1994, 20, 141-145.	0.0	7
483	Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. A study of 150 patients. , 1994, 73, 42.		1
484	Hepatitis B and C Virus Infections in Hepatocellular Carcinoma and Their Prevention. , 1994, , 685-689.		4
485	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994, 19, 1321-1324.	3.6	136
486	Serial Follow-up of Hepatitis C Virus RNA and Antibody in Infants Born to Hepatitis C Virus Positive but Human Immunodeficiency Virus Negative Mothers. , 1994, , 471-473.		0

#	ARTICLE	IF	CITATIONS
487	Low prevalence of hepatitis C virus infection among dentists in Taiwan. <i>Journal of Medical Virology</i> , 1993, 40, 10-13.	2.5	26
488	Minimal role of hepatitis C virus infection in childhood liver diseases in an area hyperendemic for hepatitis B infection. <i>Journal of Medical Virology</i> , 1993, 40, 322-325.	2.5	43
489	Comparison of Three Different Immunoassays and PCR for the Detection of Hepatitis C Virus Infection in Pregnant Women in Taiwan. <i>Vox Sanguinis</i> , 1993, 65, 117-121.	0.7	11
490	Activation of Protooncogene C-jun by the X Protein of Hepatitis B Virus. <i>Virology</i> , 1993, 192, 346-350.	1.1	124
491	Hepatitis Delta Virus cDNA Monomer Can Be Used in Transfection Experiments to Initiate Viral RNA Replication. <i>Virology</i> , 1993, 197, 137-142.	1.1	26
492	Immunoglobulin M antibodies against hepatitis C virus antigens: significance and applications. <i>Gastroenterologia Japonica</i> , 1993, 28, 67-70.	0.4	1
493	Safety and immunogenicity of hepatitis A vaccine in healthy adult volunteers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 338-341.	1.4	10
494	Natural history of chronic hepatitis B virus infection: New light on an old story. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 470-475.	1.4	64
495	Absence or delayed appearance of hepatitis B core antibody in chronic hepatitis B surface antigen carrier children. <i>Journal of Hepatology</i> , 1993, 17, 150-154.	1.8	18
496	Prevalence of hepatitis C viral infection in a community in Taiwan. <i>Journal of Hepatology</i> , 1993, 17, 192-198.	1.8	40
497	Association of HLA-DR14 and DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. <i>Vaccine</i> , 1993, 11, 1437-1440.	1.7	30
498	Sexual transmission of HCV. <i>Lancet, The</i> , 1993, 342, 626.	6.3	16
499	Cytogenetic studies on human liver cancer cell lines. <i>Cancer Genetics and Cytogenetics</i> , 1993, 65, 161-166.	1.0	22
500	Acute Jejuno gastric Intussusception – A Case Report. <i>Digestive Endoscopy</i> , 1993, 5, 404-408.	1.3	3
501	Hepatitis B Virus in the Colostra of HBeAg-Positive Carrier Mothers. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1993, 17, 207-210.	0.9	39
502	Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. <i>Gastroenterology</i> , 1993, 105, 583-587.	0.6	93
503	Comparison of Three Different Immunoassays and PCR for the Detection of Hepatitis C Virus Infection in Pregnant Women in Taiwan. <i>Vox Sanguinis</i> , 1993, 65, 117-121.	0.7	11
504	Multiple hepatocellular carcinomas at the early stage have different clonality. <i>Gastroenterology</i> , 1993, 105, 1471-1476.	0.6	58

#	ARTICLE	IF	CITATIONS
505	Structure and Expression of Mouse Î±1-Acid Glycoprotein Gene-3 (AGP-3). <i>DNA and Cell Biology</i> , 1992, 11, 315-320.	0.9	7
506	Intrafamilial Transmission of Hepatitis C Virus: The Important Role of Infections between Spouses. <i>Journal of Infectious Diseases</i> , 1992, 166, 900-903.	1.9	148
507	Posttransfusion hepatitis revisited by hepatitis C antibody assays and polymerase chain reaction. <i>Gastroenterology</i> , 1992, 103, 609-616.	0.6	33
508	Hepatitis C and B viruses in hepatitis B Surface antigen-negative hepatocellular carcinoma. <i>Gastroenterology</i> , 1992, 103, 1322-1327.	0.6	133
509	Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 5971-5975.	3.3	60
510	Improved gene expression by a U3-based retroviral vector. <i>Biochemical and Biophysical Research Communications</i> , 1992, 184, 330-337.	1.0	10
511	Improved Serodiagnosis of Posttransfusion Hepatitis C Virus Infection by a Second-Generation Immunoassay Based on Multiple Recombinant Antigens. <i>Vox Sanguinis</i> , 1992, 62, 21-24.	0.7	2
512	The Taiwanese hepatitis C virus genome: Sequence determination and mapping the 5' termini of viral genomic and antigenomic RNA. <i>Virology</i> , 1992, 188, 102-113.	1.1	210
513	Improved Serodiagnosis of Posttransfusion Hepatitis C Virus Infection by a Second-Generation Immunoassay Based on Multiple Recombinant Antigens. <i>Vox Sanguinis</i> , 1992, 62, 21-24.	0.7	30
514	Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. <i>Hepatology</i> , 1992, 15, 382-386.	3.6	77
515	Cellular Immune Response to HBcAg in Mother-to-Infant Transmission of Hepatitis B Virus. <i>Hepatology</i> , 1992, 15, 770-776.	3.6	126
516	Hepatitis C virus RNA in saliva of patients with posttransfusion hepatitis and low efficiency of transmission among spouses. <i>Journal of Medical Virology</i> , 1992, 36, 28-31.	2.5	75
517	Prevalence of anti-HCV and HCV viremia in hemodialysis patients in Taiwan. <i>Journal of Medical Virology</i> , 1992, 37, 108-112.	2.5	56
518	A prospective study of posttransfusion hepatitis in Taiwan. <i>Journal of Hepatology</i> , 1991, 13, 38-43.	1.8	26
519	Hepatitis C virus RNA in saliva of patients with post-transfusion hepatitis C infection. <i>Lancet, The</i> , 1991, 337, 48.	6.3	52
520	Low-power laserthermia for the treatment of small hepatocellular carcinoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1622-1627.	0.9	48
521	Laserthermia for the Treatment of Small Hepatocellular Carcinoma: A Preliminary Study. <i>Photomedicine and Laser Surgery</i> , 1991, 9, 195-197.	1.1	4
522	Temporal aspects of major viral transcript expression in hep G2 cells transfected with cloned hepatitis B virus DNA: With emphasis on the X transcript. <i>Virology</i> , 1991, 185, 644-651.	1.1	35

#	ARTICLE	IF	CITATIONS
523	Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. <i>Hepatology</i> , 1991, 13, 316-320.	3.6	83
524	Isolation of a complementary DNA fragment of hepatitis C virus in Taiwan revealed significant sequence variations compared with other isolates. <i>Hepatology</i> , 1991, 14, 73-78.	3.6	35
525	Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: Five years after a mass hepatitis B vaccination program. <i>Journal of Medical Virology</i> , 1991, 34, 96-99.	2.5	95
526	Recombinant immunoblot assay for hepatitis C antibody in patients with posttransfusion non-A, non-B hepatitis. <i>Journal of Medical Virology</i> , 1991, 34, 172-175.	2.5	6
527	Non-A, non-B hepatitis in children: A clinical, histologic, and serologic study. <i>Journal of Medical Virology</i> , 1991, 35, 1-6.	2.5	28
528	Low prevalence of hepatitis C virus and infrequent perinatal or spouse infections in pregnant women in Taiwan. <i>Journal of Medical Virology</i> , 1991, 35, 237-240.	2.5	26
529	Hepatitis C virus infection in Taiwan. <i>Gastroenterologia Japonica</i> , 1991, 26, 164-166.	0.4	29
530	Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. <i>Hepatology</i> , 1991, 13, 316-320.	3.6	8
531	Prognostic Implications of Serum α -Fetoprotein Levels in Neonatal Hepatitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1990, 11, 27-31.	0.9	6
532	Complete Agenesis of the Dorsal Pancreas—A Case Report and Review of the Literature. <i>Pancreas</i> , 1990, 5, 493-497.	0.5	24
533	Laserthermia for the treatment of small hepatocellular carcinoma: a preliminary study. , 1990, 1201, 620.		0
534	Plasma des- γ -carboxyprothrombin in the early stage of hepatocellular carcinoma. <i>Hepatology</i> , 1990, 11, 481-487.	3.6	109
535	Identification and characterization of intrahepatic hepatitis b virus dna in hbsag-seronegative patients with chronic liver disease and hepatocellular carcinoma in Taiwan. <i>Hepatology</i> , 1990, 12, 575-581.	3.6	58
536	Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children. <i>Hepatology</i> , 1990, 12, 657-660.	3.6	84
537	Detection of hepatitis B viral DNA by polymerase chain reaction in patients with hepatitis B surface antigen. <i>Journal of Medical Virology</i> , 1990, 30, 159-162.	2.5	21
538	Hepatitis D virus infection among intravenous drug abusers in Taiwan: Analysis of risk factors and liver function tests. <i>Journal of Medical Virology</i> , 1990, 31, 76-81.	2.5	11
539	Hepatitis C virus in a prospective study of posttransfusion non-A, non-B hepatitis in Taiwan. <i>Journal of Medical Virology</i> , 1990, 32, 83-86.	2.5	43
540	Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction. <i>Journal of Medical Virology</i> , 1990, 32, 257-260.	2.5	66

#	ARTICLE	IF	CITATIONS
541	Molecular Cloning of cDNAs Corresponding to Two Genes of Î±1-Acid Glycoprotein and Characterization of Two Alleles of ACP-1 in the Mouse. <i>DNA and Cell Biology</i> , 1989, 8, 245-251.	5.1	27
542	Characterization of the Transcripts of Hepatitis D and B Viruses in Infected Human Livers. <i>Journal of Infectious Diseases</i> , 1989, 160, 944-947.	1.9	5
543	Biologic significance of the detection of HBsAg and HBcAg in liver and tumor from 204 HBsAg-positive patients with primary hepatocellular carcinoma. <i>Hepatology</i> , 1989, 9, 747-750.	3.6	27
544	Postpartum subsidence of hepatitis B viral replication in hbeag-positive carrier mothers. <i>Journal of Medical Virology</i> , 1989, 29, 1-6.	2.5	58
545	Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. <i>Cancer</i> , 1989, 64, 2377-2380.	2.0	112
546	Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. <i>Journal of Pediatrics</i> , 1989, 115, 385-390.	0.9	108
547	Changing aetiologic patterns of acute viral hepatitis in Taiwanese children. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1989, 4, 339-344.	1.4	2
548	Serum Î±-Fetoprotein Levels in Normal Infants. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1989, 8, 19-25.	0.9	20
549	Clonal Origin of Recurrent Hepatocellular Carcinomas. <i>Gastroenterology</i> , 1989, 96, 527-529.	0.6	130
550	Pleural effusion coinciding with acute exacerbations in a patient with chronic hepatitis B. <i>Gastroenterology</i> , 1989, 96, 1604-1606.	0.6	6
551	Tumor invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications. <i>Cancer</i> , 1988, 61, 2095-2099.	2.0	111
552	Evolution of expression of hepatitis B surface and core antigens (HBsAg, HBcAg) in resected primary and recurrent hepatocellular carcinoma in HBsAg carriers in Taiwan. Correlation with local host immune response. <i>Cancer</i> , 1988, 62, 915-921.	2.0	12
553	Status of hepatitis B virus DNA in hepatocellular carcinoma: A study based on paired tumor and nontumor liver tissues. <i>Journal of Medical Virology</i> , 1988, 25, 249-258.	2.5	29
554	Pathology of chronic hepatitis b virus infection in children: With special reference to the intrahepatic expression of hepatitis B virus antigens. <i>Hepatology</i> , 1988, 8, 378-382.	3.6	41
555	Detection of hepatitis B virus dna in hepatocellular carcinoma: Analysis by hybridization with subgenomic dna fragments. <i>Hepatology</i> , 1988, 8, 518-523.	3.6	32
556	Correlation of hepatocyte HBsAg expression with virus replication and liver pathology. <i>Hepatology</i> , 1988, 8, 749-754.	3.6	55
557	Î± Infection in asymptomatic carriers of hepatitis B surface antigen: Low prevalence of Î± activity and effective suppression of hepatitis B virus replication. <i>Hepatology</i> , 1988, 8, 1121-1124.	3.6	56
558	Hepatitis D virus infection in children with acute or chronic hepatitis B virus infection in Taiwan. <i>Journal of Pediatrics</i> , 1988, 112, 888-892.	0.9	21

#	ARTICLE	IF	CITATIONS
559	Induction of an alu-sequence containing transcript by insulin in human hepatoma cells. <i>Biochemical and Biophysical Research Communications</i> , 1988, 156, 1287-1292.	1.0	3
560	Fulminant hepatitis in infants in Taiwan: Strong association with hepatitis B e antigen-negative but antibody-positive maternal hepatitis B surface antigen carriage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1988, 3, 1-7.	1.4	5
561	Natural history of hepatitis B surface antigen-positive cirrhosis in Taiwan: A clinicopathological study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1988, 3, 583-592.	1.4	10
562	Carcinoma of the Gallbladder from an Anomalous Connection between the Bile Duct and the Pancreatic Duct. <i>Journal of Clinical Gastroenterology</i> , 1988, 10, 335-338.	1.1	4
563	Pancreatic Carcinoma Associated With Chronic Calcifying Pancreatitis in Taiwan. <i>Pancreas</i> , 1988, 3, 111-114.	0.5	12
564	A Mass Vaccination Program in Taiwan Against Hepatitis B Virus Infection in Infants of Hepatitis B Surface Antigen Carrier Mothers. <i>JAMA - Journal of the American Medical Association</i> , 1987, 257, 2597.	3.8	250
565	Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. <i>Journal of Pediatrics</i> , 1987, 111, 877-881.	0.9	135
566	Fulminant hepatitis in children in Taiwan: The important role of hepatitis B virus. <i>Journal of Pediatrics</i> , 1987, 111, 34-39.	0.9	80
567	Delta-agent infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 1-8.	1.4	18
568	Hepatitis B e antigen and its antibody in chronic type B hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 255-270.	1.4	9
569	Studies on duck hepatitis B virus: Identification and epidemiological survey in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 423-429.	1.4	0
570	Clearance of hepatitis B surface antigen (HBsAg) after surgical resection of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1987, 4, 45-51.	1.8	36
571	Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. <i>Journal of Hepatology</i> , 1987, 5, 260-267.	1.8	83
572	Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 1987, 5, 45-50.	1.8	113
573	Reduced doses of hepatitis B immune globulin in the prevention of perinatal transmission of hepatitis B. <i>Journal of Medical Virology</i> , 1987, 21, 301-309.	2.5	1
574	Cytophotometric measurements of nuclear DNA content in hepatocellular carcinomas. <i>Hepatology</i> , 1987, 7, 330-332.	3.6	36
575	DNA clonal heterogeneity of hepatocellular carcinoma demonstrated by Feulgen DNA analysis. <i>Liver</i> , 1987, 7, 359-363.	0.1	27
576	Hepatitis B Virus Infection, Its Sequelae, and Prevention in Taiwan. , 1987, , 71-80.		66

#	ARTICLE	IF	CITATIONS
577	Diverse virological, histopathological and prognostic implications of seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 1986, 3, 182-189.	1.8	49
578	Noninvasive Diagnosis of Advanced Pancreatic Cancer by Real-Time Ultrasonography, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9. <i>Pancreas</i> , 1986, 1, 219-223.	0.5	13
579	Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: A study just before mass hepatitis B vaccination program in Taiwan. <i>Journal of Medical Virology</i> , 1986, 18, 301-307.	2.5	192
580	Serum HBsAg, HBeAg, anti-HBe, and hepatitis B viral DNA in asymptomatic carriers in Taiwan. <i>Journal of Medical Virology</i> , 1986, 19, 87-94.	2.5	37
581	Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. <i>Gastroenterology</i> , 1985, 89, 259-266.	0.6	400
582	Delta agent in nondrug addicts. <i>Hepatology</i> , 1985, 5, 526-528.	3.6	0
583	Persistence of IgM hepatitis A antibody after clinical type A hepatitis. <i>Hepatology</i> , 1985, 5, 705-705.	3.6	4
584	Inadequacy of Immunoglobulin M hepatitis B core antibody in detecting acute hepatitis B virus infection in infants of HBsAg carrier mothers. <i>Journal of Medical Virology</i> , 1985, 16, 309-314.	2.5	17
585	Changing seroepidemiology of hepatitis A virus infection in Taiwan. <i>Journal of Medical Virology</i> , 1985, 17, 297-301.	2.5	49
586	Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. <i>Cancer</i> , 1985, 56, 660-666.	2.0	217
587	Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan. A comparison with resected large HCC. <i>Cancer</i> , 1985, 56, 672-680.	2.0	134
588	Serum α -Fetoprotein in the Early Stage of Human Hepatocellular Carcinoma. <i>Gastroenterology</i> , 1984, 86, 1404-1409.	0.6	187
589	δ Agent Infection in Patients with Chronic Liver Diseases and Hepatocellular Carcinoma-An Infrequent Finding in Taiwan. <i>Hepatology</i> , 1984, 4, 502-503.	3.6	89
590	Fraternal hepatocellular carcinoma in young children in two families. <i>Cancer</i> , 1984, 53, 1807-1810.	2.0	34
591	HBeAg and anti-HBe in chronic hepatitis B virus infection. <i>Gastroenterology</i> , 1981, 80, 880-881.	0.6	12
592	Relationship of hepatitis b surface antigen to serum alpha-fetoprotein in nonmalignant diseases of the liver. <i>Cancer</i> , 1979, 44, 984-992.	2.0	61
593	Serum alphafetoprotein in hepatocellular carcinoma. <i>Cancer</i> , 1977, 40, 779-783.	2.0	151
594	Geographical distribution of the subtype of hepatitis b surface antigen in chinese. <i>Gastroenterologia Japonica</i> , 1977, 12, 58-63.	0.4	21

#	ARTICLE	IF	CITATIONS
595	Overview of Hepatitis B and C Viruses. , 0, , 313-330.		27